GWSFF News and Press, Glb Wellness Strategies

Vancouver, British Columbia--(Newsfile Corp. - October 5, 2023) - Xtacy Therapeutics Corp. (CSE: XTCY) (FSE: TT5) (OTCQB: GWSFF) (formerly Global Wellness Strategies Inc.) ("the Company") announces that it has agreed to settle an aggregate of CA$118,075 in debt through the issuance of...

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X) (OTCQB: GWSFF) ("Global Wellness" or the "Company" ) pharma subsidiary is excited to work with BioMed360 a GWS medical advisor. GWS pharma subsidiary is focused on providing ...

Vancouver, British Columbia--(Newsfile Corp. - November 17, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X) (OTCQB: GWSFF) ("Global" or the "Company" ) a prospect generator that provides high growth companies with financial, operational, and management assistance focused in heal...

Vancouver, British Columbia--(Newsfile Corp. - June 27, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X4) (OTCQB: GWSFF) ("Global" or the "Company") provides quarter corporate highlights. The Company quarter corporate highlights included announcing: May 12 th that Global Well...

Shanti's Focus on Chronic Pain Market with Psychedelics Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - Global Wellness Strategies Inc. ( CSE: GWS) (OTCQB: GWSFF) (FSE: O3X) ("Global" or the "Company") announces Shanti Therapeutics MDMA Clinical Trial Update. Shanti's produ...

Vancouver, British Columbia--(Newsfile Corp. - February 22, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X4) (OTCQB: GWSFF) ("Global" or the "Company") is pleased to announce the first tranche closing of its non-brokered private placement (the "Offering") for gross proceeds of ...

The Shanti Therapeutics Focus on Chronic Pain Market with Psychedelics Vancouver, British Columbia--(Newsfile Corp. - February 10, 2022) - Global Wellness Strategies Inc. (CSE: GWS) (FSE: O3X4) (OTCQB: GWSFF) ("Global" or the "Company") and their Contract Research Organization ("CRO") iNGEN&...

Next Frontier Pharmaceuticals' Subsidiary Benuvia Signs Agreement with Global Wellness' Shanti Therapeutics Benuvia has begun focusing on Psilocybin, DMT, and MDMA. Benuvia's 83,000 square foot synthetic compound manufacturing facility is permitted by the U.S. DEA for Schedule I to I...